New publication! @alliance_org research led by Matthew Wiedewult MD of @WakeForest shows targeted immunotherapy drugs lead to high remission rates and long survival for patients with a tough-to-treat form of leukemia. https://t.co/XmgDA9MM6P @JCO_ASCO#NCI
@dgermain21@Eddie_Cliff Most of us here have been giving ino/ blin per A041703. MiniCVD ino the way it was published has excessive late toxicity in the 70+ population unless you limit to 2 cycles
kudos to @DrWendyStock@CanerSaygin who are co-authors on a high-impact publication of Inotuzumab + blinatumomab in older adults with B-ALL!
https://t.co/1AP3X7nZa8
Testing for certain features in cancer (biomarkers) can tell doctors about what’s causing it to grow. The #myeloMATCH study uses advanced biomarker testing for adults with #AML or #MDS. @theNCI@ALLIANCE_org@CDNCancerTrials@eaonc@SWOG 1-800-4-CANCER or
https://t.co/zFoHpiw2KU
For #TrialTuesday, .@LuskinMarlise@DanaFarber leads ALLIANCE_org A042001, a trial to compare targeted therapy & chemotherapy w/standard treatment for pts w/B-cell acute lymphoblastic #leukemia or B-cell lymphoblastic #lymphoma w/targeted therapy: https://t.co/jyAdggs7Vu @LLSusa
E. Donnall Thomas lecturer @DiPersioLab introduces his lecture, "Is Transplantation Only Copacetic? A Personal Tale of Mentors, Trainees and Colleagues." Register for #Tandem24 & attend his lecture, taking place Feb. 23, 5:50 - 6:20 PM CT. Learn more: https://t.co/S4pfMLfpmx
Please spread the message and help find these rare patients for this clinical trial for IDH1 mutated CCUS. The study is decentralized. Patients can be anywhere in the US and do not have to travel to St Louis to participate. #leusm
In 2021, @KellyLBolton and colleagues launched an unusual clinical study that not only evaluated one of the first potential genetically targeted preventative therapies for cancer, but may also help to reshape the future of clinical trials. Read more: https://t.co/xex7v9b2K4
Celebrating Dr. @MRLitzow at the @eaonc annual meeting. Mark led the #leukemia committee for 9 years, has contributed so much to improving treatment for pts with heme malignancies,& has been an incredible mentor and role model for so many of us. His dedication is unmatched.
Celebrating Dr. @MRLitzow at the @eaonc annual meeting. Mark led the #leukemia committee for 9 years, has contributed so much to improving treatment for pts with heme malignancies,& has been an incredible mentor and role model for so many of us. His dedication is unmatched.
@Dr_AmerZeidan There are multiple perspectives and for those who are interested, this provides some insight as to why the ICC was created.
https://t.co/8FSQSMR2Pm
@TalhaBadarMD Love this. I can summarize.
DFCI: 7+3+midostaurin
Hopkins: Needs a haplo
Wash U: Needs to check serial error corrected NGS
U of C: Need to check for inherited variants
MDACC: CLAG-Ida/Ven/gilt alt with LDAC -> 98%OS
@VPrasadMDMPH your definition of “cure“ ignores the reality that patients suffer from late effects of their cancer treatment.
https://t.co/se5opoSvVj
#ASH22
@LeonidasPlatan1@elonmusk Twitter is for congratulating people on their accomplishments and funny animal pictures. The most vocal in medical debates on Twitter are almost never the true experts in the field.
#WUDeptMedicine announces new leadership for Division of Oncology. Read full announcement from Victoria Fraser, MD, Chair, Department of Medicine here: https://t.co/oJeXoLjTTL
@WUSTLmed